Physician

Casey Farin Jeffreys, M.D.

According to 2025 Medicare claims, Casey Jeffreys, M.D. (NPI: 1619395092) practices neurology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is RALEIGH NEUROLOGY ASSOCIATES, P. A. (NPI: 1215954003; TIN: 562002729) and primary practice location at 27607-5253.

Jeffreys' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 427 traditional Medicare patients, billed 51,361 HCPCS/CPT codes, and received $1,288,518 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 4,241 prescription claims across 527 beneficiaries totaling $5,034,716 in drug costs, led by Kesimpta Pen (Ofatumumab). DME data shows 12 claims. Open Payments data shows 284 records totaling $725,293. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $264,763 to $1,288,518. Similarly, Part D prescription costs have moved sharply higher in recent years, from $27,845 to $5,034,716. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	138	8,512	$264,763
2020	334	24,752	$602,682
2021	396	17,454	$281,688
2022	429	16,993	$296,279
2023	364	31,065	$720,977
2024	427	51,361	$1,288,518

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	61	346	$27,845
2016	26	119	$10,448
2017	15	50	$4,871
2018	N/R	26	$1,198
2019	104	246	$29,698
2020	274	1,631	$1,377,215
2021	440	3,558	$3,252,464
2022	532	4,749	$4,954,400
2023	494	3,949	$5,044,453
2024	527	4,241	$5,034,716

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$97
2022	N/R	N/R	N/R
2023	N/R	12	$170
2024	N/R	12	$3,368

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	53	53	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	181	251	$82
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	59	59	$64
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	73	116	$44
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	195	278	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kesimpta Pen	Ofatumumab	89	2,572	$845,238
Ocrevus	Ocrelizumab	19	2,560	$783,679
Avonex (4 Pack)	Interferon Beta-1a	66	1,848	$589,721
Rebif	Interferon Beta-1a/Albumin	37	1,032	$416,534
Avonex Pen (4 Pack)	Interferon Beta-1a	25	1,148	$340,167

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	12	$3,368

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	281	$12,494	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$712,800	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Casey Farin Jeffreys, M.D.?

Tedicare shows public-source Medicare data for Casey Farin Jeffreys, M.D. (NPI 1619395092), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Casey Farin Jeffreys, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Casey Farin Jeffreys, M.D.?

Casey Farin Jeffreys, M.D. is linked to RALEIGH NEUROLOGY ASSOCIATES, P. A. (billing NPI 1215954003) in the available physician profile data.

Does Casey Farin Jeffreys, M.D. have Open Payments data?

Casey Farin Jeffreys, M.D. has 284 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.